Metagenomi Therapeutics (MGX) EBT (2023 - 2026)

Metagenomi Therapeutics (MGX) has reported EBT for 4 consecutive years, with -$27.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBT fell 38.35% year-over-year to -$27.5 million in Q2 2026; TTM through Jun 2026 was -$93.7 million, a 3.72% decrease from a year earlier, with the FY2025 full-year figure at -$87.9 million, down 5.21% from the prior year.
• EBT was -$27.5 million for Q2 2026 at Metagenomi Therapeutics, down from -$23.0 million in the prior quarter.
• Over five years, EBT peaked at -$11.1 million in Q2 2023 and troughed at -$27.5 million in Q2 2026.
• A 4-year average of -$20.2 million and a median of -$20.8 million in 2024 frame the typical range for EBT.
• Across the five-year window, EBT sank 80.45% in 2024 and advanced 8.58% in 2025, its largest moves.
• Over 4 years, EBT stood at -$16.6 million in 2023, then tumbled by 48.52% to -$24.6 million in 2024, then climbed by 8.58% to -$22.5 million in 2025, then decreased by 22.17% to -$27.5 million in 2026.
• The last three EBT figures came in at -$27.5 million (Q2 2026), -$23.0 million (Q1 2026), and -$22.5 million (Q4 2025), per Business Quant data.